SEARCH

SEARCH BY CITATION

8.1.3 References

  • 1
    Pozniak AL, Coyne KM, Miller RF et al.; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med 2011; 12: 517524.
  • 2
    Dean GL, Edwards SG, Ives NJ et al. Treatment of tuberculosis in HIV-1 infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 7583.
  • 3
    Abdoolkarim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697706.
  • 4
    Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 14821491.
  • 5
    Blanc F-X, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 14711481.
  • 6
    Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563608.
  • 7
    Torok ME, Yen NT, Chau TT et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52: 13741383.
  • 8
    Friedland G, Khoo S, Jack C et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58: 12991302.
  • 9
    Manosuthi W, Kiertiburanakul S, Sungkanuparph S et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131132.
  • 10
    Boulle A, Van Cutsem G, Cohen K et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when co-administered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530539.
  • 11
    Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681690.
  • 12
    Manosuthi W, Sungkanuparph S, Thakkinstian A et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19: 14811486.
  • 13
    Ngaimisi E, Mugusi S, Minzi O et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz auto induction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacother 2011; 90: 406413.
  • 14
    Manosuthi W, Sungkanuparph S, Tantanathip P et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48: 17521759.
  • 15
    Avihingsanon A, Manosuthi W, Kantipong P et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis co-infection receiving rifampicin. Antivir Ther 2008; 13: 529536.
  • 16
    Bonnet M, Bhatt N, Baudin E et al. Results of the CARINEMO-ANRS 12146 randomized trial comparing the efficacy and safety of nevirapine versus efavirenz for treatment of HIV-TB co-infected patients in Mozambique. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention . Rome, Italy. August 2011 [Abstract WELBX05].
  • 17
    Laporte C, Colbers E, Bertz R et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 15531560.
  • 18
    Acosta EP, Kendall MA, Gerber JG et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51: 31043110.
  • 19
    Ribera E, Azuaje C, Lopez RM et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59: 690697.
  • 20
    Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009; 2: 816.
  • 21
    Haas DW, Koletar SL, Laughlin L et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50: 290293.
  • 22
    Nijland HM, l'homme RF, Rongen GA et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22: 931935.
  • 23
    Narita M, Stambaugh JJ, Hollender ES et al. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779783.
  • 24
    Boulanger C, Hollender E, Farrell K et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 13051311.
  • 25
    Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48: 14711474.
  • 26
    Naiker S, Conolly C, Weisner L et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. 18th Conference on Retroviruses and Opportunistic Infections . Boston, MA. February 2011 [Abstract 650].
  • 27
    Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 14811491.
  • 28
    Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009; 64: 871873.
  • 29
    Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995; 29: 11491155.
  • 30
    Cato A 3rd, Cavanaugh J, Shi H et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414421.

8.2.4 References

  • 1
    Brook G, Main J, Nelson M et al. BHIVA Viral Hepatitis Working Group. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11: 130.
  • 2
    Soriano V, Puoti M, Peters M et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV/hepatitis B virus international panel. AIDS 2008; 22: 13991410.
  • 3
    Marcellin P, Buti M, Gane EJ et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54 (Suppl 1): Abstract 1375.
  • 4
    Matthews G, Bartholomeusz A, Locarnini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863870.
  • 5
    Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 13021306.
  • 6
    Jain MK, Comanor L, White C et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007; 14: 176182.
  • 7
    Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 18001805.
  • 8
    Rockstroh JK, Mocroft A, Soriano V et al. for the EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 9921002.
  • 9
    Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755.
  • 10
    Reiberger T. HIV–HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17: 400409.
  • 11
    Macías J, Berenguer J, Japón MA et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 10561063.
  • 12
    Thein HH, Yi Q, Dore GJ et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 19791991.
  • 13
    Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 14
    Garcia-Samaniego J, Rodriguez M, Berenguer J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179183.
  • 15
    Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 22092216.
  • 16
    Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009; 15: 552558.
  • 17
    Merchante N, Girón-González JA, González-Serrano M et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 4957.
  • 18
    Pineda JA, García-García JA, Aguilar-Guisado M et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622630.
  • 19
    Ragni MV, Im K, Neff G et al. Survival in HIV-infected liver transplant recipients. J Infect Dis 2003; 118: 14121420.
  • 20
    Mehta SH, Thomas DL, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41: 123131.
  • 21
    Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. 18th Conference on Retroviruses and Opportunistic Infections . Boston MA. February 2011 [Abstract 118].
  • 22
    van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic Interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections . Boston MA. February 2011 [Abstract 119].
  • 23
    Sulkowski M, Dieterich D, Sherman K et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st ICAAC . Chicago, IL. September 2011 [Abstract 1738a].
  • 24
    Rockstroh J, Adda N, Mahnke L et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV/HCV co-infected patients. 18th Conference on Retroviruses and Opportunistic Infections . Boston MA. February 2011 [Abstract 146LB].
  • 25
    Hulskotte EGJ, Feng H-P XF et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. 19th Conference on Retroviruses and Opportunistic Infections . Seattle, WA. February 2012 [Abstract 771LB].
  • 26
    de Kanter C, Blonk M, Colbers A, Fillekes Q, Schouwenberg B, Burger D. The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase inhibitor raltegravir. 19th Conference on Retroviruses and Opportunistic Infections . Seattle, WA. February 2012 [Abstract 772LB].

8.3.5 References

  • 1
    Jacobson LP, Yamashita TE, Detels R et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999; 21 (Suppl 1): S34S41.
  • 2
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 18231830.
  • 3
    Portsmouth S, Stebbing J, Gill J et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17: F17F22.
  • 4
    Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425432.
  • 5
    Bower M, Fox P, Fife K et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 21052111.
  • 6
    Stebbing J, Sanitt A, Nelson M et al. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367: 14951502.
  • 7
    Holkova B, Takeshita K, Cheng DM et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001; 19: 38483851.
  • 8
    Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98: 916922.
  • 9
    Bower M, Weir J, Francis N et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS 2009; 23: 17011706.
  • 10
    Stebbing J, Gazzard B, Mandalia S et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 21772183.
  • 11
    Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 34063412.
  • 12
    Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 23392344.
  • 13
    Grulich AE, Li Y, McDonald AM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15: 629633.
  • 14
    Carrieri MP, Pradier C, Piselli P et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003; 103: 142144.
  • 15
    Franceschi S, Dal Maso L, Pezzotti P et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. J Acquir Immune Defic Syndr 2003; 34: 8490.
  • 16
    Diamond C, Taylor TH, Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol 2006; 24: 139145.
  • 17
    Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006; 20: 16451654.
  • 18
    Bower M, Fisher M, Hill T et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94: 875880.
  • 19
    Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909915.
  • 20
    Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155163.
  • 21
    Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23: 84778482.
  • 22
    Lim ST, Karim R, Nathwani BN et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23: 44304438.
  • 23
    Kaplan LD, Abrams DI, Feigal E et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261: 719724.
  • 24
    Kaplan LD, Straus DJ, Testa MA et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 16411648.
  • 25
    Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22: 26622670.
  • 26
    Bower M, Stebbing J, Tuthill M et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 2008; 111: 39863990.
  • 27
    Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531536.
  • 28
    Little R, Pearson D, Steinberg S et al. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1999; 18: 10a.
  • 29
    Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101: 46534659.
  • 30
    Dunleavy K, Little RF, Pittaluga S et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010; 115: 30173024.
  • 31
    Sparano JA, Lee JY, Kaplan LD et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115: 30083016.
  • 32
    Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98: 10781085.
  • 33
    Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 11201130.
  • 34
    Engels EA, Biggar RJ, Hall HI et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187194.
  • 35
    Dal Maso L, Polesel J, Serraino D et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100: 840847.
  • 36
    Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 14591464.
  • 37
    Minkoff H, Ahdieh L, Massad LS et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15: 21572164.
  • 38
    Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16: 17991802.
  • 39
    Schuman P, Ohmit SE, Klein RS et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188: 128136.
  • 40
    Ahdieh-Grant L, Li R, Levine AM et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96: 10701076.
  • 41
    Del Mistro A, Bertorelle R, Franzetti M et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38: 737742.
  • 42
    Soncini E, Zoncada A, Condemi V et al. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78: 3640.
  • 43
    Lillo FB, Ferrari D, Veglia F et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547551.
  • 44
    Moore AL, Sabin CA, Madge S et al. Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS 2002; 16: 927929.
  • 45
    Heard I, Potard V, Costagliola D. Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. Antivir Ther 2006; 11: 10911096.
  • 46
    Sirera G, Videla S, Lopez-Blazquez R et al. Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3 . J Antimicrob Chemother 2008; 61: 191194.
  • 47
    Wichmann MW, Meyer G, Adam M et al. Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum 2003; 46: 875887.
  • 48
    Wexler A, Berson AM, Goldstone SE et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008; 51: 7381.
  • 49
    Fraunholz I, Weiss C, Eberlein K, Haberl A, Rodel C. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 2010; 76: 14251432.
  • 50
    Alfa-Wali M, Allen-Mersh T, Antoniou A et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol 2011; 23: 141147.
  • 51
    Blazy A, Hennequin C, Gornet JM et al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48: 11761181.
  • 52
    Oehler-Janne C, Huguet F, Provencher S et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 25502557.
  • 53
    Seo Y, Kinsella MT, Reynolds HL. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009; 75: 143149.
  • 54
    Hogg ME, Popowich DA, Wang EC. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum 2009; 52: 891897.
  • 55
    Vatra B, Sobhani I, Aparicio T et al. [Anal canal squamous-cell carcinomas in HIV positive patients: clinical features, treatments and prognosis]. Gastroenterol Clin Biol 2002; 26: 150156.
  • 56
    Abramowitz L, Mathieu N, Roudot-Thoraval F et al. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther 2009; 30: 414421.
  • 57
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 5967.
  • 58
    Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21: 34473453.
  • 59
    Bedimo R, Chen RY, Accortt NA et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis 2004; 39: 13801384.
  • 60
    Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17: 371375.
  • 61
    Hessol NA, Seaberg EC, Preston-Martin S et al. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 36: 978985.
  • 62
    Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 489496.
  • 63
    Patel P, Hanson DL, Sullivan PS et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148: 728736.
  • 64
    Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884900.
  • 65
    Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12: 905912.
  • 66
    Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44: 111145.
  • 67
    Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445454.
  • 68
    Bower M, McCall-Peat N, Ryan N et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104: 29432946.
  • 69
    Mir O, Dessard-Diana B, Louet AL et al. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol 2010; 69: 99101.
  • 70
    Corona G, Vaccher E, Sandron S et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008; 83: 601606.
  • 71
    Kotb R, Vincent I, Dulioust A et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006; 76: 269271.
  • 72
    Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010; 5: 209217.
  • 73
    Wasserman E, Myara A, Lokiec F et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 10491051.
  • 74
    Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26: 9297.
  • 75
    Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19: 481494.

8.4.5 References

  • 1
    Dore GJ, Correll PK, Li Y et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13: 12491253.
  • 2
    Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 17891799.
  • 3
    Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 2011; 53: 836842.
  • 4
    Heaton RK, Clifford DB, Franklin DR Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2011; 75: 20872096.
  • 5
    Simioni S, Cavassini M, Annoni JM et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 12431250.
  • 6
    Ellis RJ, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25: 17471751.
  • 7
    Wright EJ, Grund B, Robertson K et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2011; 75: 864873.
  • 8
    Al-Khindi T, Zakzanis KK, van Gorp WG. Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature. J Int Neuropsychol Soc 2011; 17: 114.
  • 9
    Cysique LA, Vaida F, Letendre S et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342348.
  • 10
    Winston A, Puls R, Kerr SJ et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med 2012; 13: 245251.
  • 11
    Schmitt FA, Bigley JW, McKinnis R et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 15731578.
  • 12
    d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320328.
  • 13
    Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 6570.
  • 14
    Tozzi V, Balestra P, Salvatori MF et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52: 5663.
  • 15
    Smurzynski M, Wu K, Letendre S et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357365.
  • 16
    Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 13591366.
  • 17
    Winston A, Duncombe C, Li PC et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50: 920929.
  • 18
    Schweinsburg BC, Taylor MJ, Alhassoon OM et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11: 356364.
  • 19
    Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 2011; 66: 19541962.
  • 20
    Katlama C, Valantin MA, Algarte-Genin M et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 23652374.
  • 21
    Gutmann C, Cusini A, Günthard HF et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24: 23472354.
  • 22
    Paton NI, Meynard JL, Pulido F et al. Inappropriate claim of ′failure of ritonavir-boosted lopinavir monotherapy in HIV′ in the Monotherapy Switzerland/Thailand (MOST) trial. AIDS 2011; 25: 393394.
  • 23
    Winston A, Fätkenheuer G, Arribas J et al. Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. HIV Clin Trials 2010; 11: 163169.
  • 24
    Garvey L, Higgs C, Mohammed P et al. Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues. AIDS Res Hum Retroviruses 2011; 27: 701703.
  • 25
    Brew BJ, Halman M, Catalan J et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2: e13.
  • 26
    Schifitto G, Navia BA, Yiannoutsos CT et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007; 21: 18771886.
  • 27
    Schifitto G, Yiannoutsos CT, Ernst T et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 2009; 73: 19751981.
  • 28
    Schifitto G, Zhong J, Gill D et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009; 15: 176186.
  • 29
    Schifitto G, Peterson DR, Zhong J et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006; 66: 919921.
  • 30
    Ho DD, Rota TR, Schooley RT et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 14931497.
  • 31
    Sönnerborg AB, Ehrnst AC, Bergdahl SK et al. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988; 2: 8993.
  • 32
    Soulié C, Fourati S, Lambert-Niclot S et al. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. AIDS 2010; 24: 24122414.
  • 33
    Canestri A, Lescure FX, Jaureguiberry S et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50: 773778.

8.5.3 References

8.6.5 References

  • 1
    Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55: 262270.
  • 2
    Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 15371548.
  • 3
    Klein D, Hurley LB, Quesenberry CP Jr et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 4
    Currier J, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506512.
  • 5
    Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 6
    Triant V, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 25062512.
  • 7
    Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245253.
  • 8
    Rasmussen LD, Engsig FN, Christensen H et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS 2011; 25: 16371646.
  • 9
    British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5): v152.
  • 10
    National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE CG67. London, 2008, reissued 2010. Available at http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf (accessed May 2012).
  • 11
    Law MG, Friis-Møller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7: 218230.
  • 12
    Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 12281238.
  • 13
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 14
    Phillips AN, Carr A, Neuhaus J et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177187.
  • 15
    Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 24092418.
  • 16
    Bozette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702710.
  • 17
    Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194200.
  • 18
    Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 2734.
  • 19
    Bonnet F, Chene G, Thiebaut R et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000–2004. HIV Med 2007; 8: 547554.
  • 20
    Lichtenstein KA, Armon C, Buchacz K et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV Outpatient Study. Clin Infect Dis 2010; 51: 435447.
  • 21
    Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 22
    Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 17231735.
  • 23
    Ding X, Andraca-Carrera E, Cooper C et al. No Association of myocardial infarction with ABC use: an FDA meta-analysis. 18th Conference on Retroviruses and Opportunistic Infections . Boston, MA. February 2011 [Abstract 808].
  • 24
    SMART/INSIGHT and D:A:D. Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17F24.
  • 25
    Obel N, Farkas DK, Kronborg G et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130136.
  • 26
    Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318330.
  • 27
    Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the HAART era. Clin Infect Dis 2011; 53: 8491.
  • 28
    Choi AI, Vittinghoff E, Deeks SG et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 12891298.
  • 29
    Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 2028.
  • 30
    Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 31
    Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 3744.
  • 32
    d'Arminio Monforte A, Reiss P, Ryom L et al. ATV-containing ART is not associated with an increased risk of cardio- or cerebrovascular events in the D:A:D study. 19th Conference on Retroviruses and Opportunistic Infections . Seattle, WA. March 2012 [Abstract 823].
  • 33
    European Medicines Agency. Celsentri Summary of Product Characteristics. 2007. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000811/WC500022190.pdf (accessed May 2012).

8.7.5 References

  • 1
    Taylor GT, Clayden P, Dhar J et al. BHIVA guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13 (Suppl. 2): 87157.
  • 2
    Health Protection Agency. HIV in the United Kingdom: 2010 Report. London, Health Protection Agency, 2010.
  • 3
    Doyal L. Challenges in researching life with HIV/AIDS: an intersectional analysis of black African migrants in London. Cult Health Sex 2009; 11: 173188.
  • 4
    Nicastri E, Leone S, Angeletti C et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60: 724732.
  • 5
    Soon G, Min M, Struble K et al. Meta-analysis of efficacy outcomes for treatment-naïve and experienced HIV-infected women in randomized controlled clinical trials (RCTs) (2000–2008). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy . Boston, September 2010 [Abstract H-1812].
  • 6
    Squires KE, Johnson M, Yang R et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 2011; 66: 363370.
  • 7
    Smith K, Tierney C, Daar E et al. Association of race/ethnicity and sex on outcomes in ACTG A5202. 18th Conference on Retroviruses and Opportunistic Infections . Boston, MA. February 2011 [Abstract 536].
  • 8
    Squires K, Bekker L, Eron J et al. Safety, tolerability, and efficacy of raltegravir (RAL) in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy . Chicago, IL. September 2011 [Abstract H2-789].
  • 9
    Cohen CJ, Andrade-Villanueva J, Clotet B et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229237.
  • 10
    Martorell C, Mayer CA, Northland R et al. Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials. Annual Meeting of the Infectious Diseases Society of America . Boston, MA. September 2011 [Abstract 404].
  • 11
    Barber TJ, Geretti AM, Anderson J et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011; 16: 805814.
  • 12
    Murri R, Lepri A, Phillips A. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the ICoNA. Study. J Acquir Immune Defic Syndr 2003; 34: 184189.
  • 13
    Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21: 835843.
  • 14
    Kempf MC, Pisu M, Dumcheva A et al. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009; 52: 336341.
  • 15
    Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 23912400.
  • 16
    Mazhude C, Jones S, Murad S. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor induced rash. AIDS 2002; 16: 15661568.
  • 17
    Sanne I, Mommeya-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825829.
  • 18
    Puskas CM, Forrest JI, Parashar S et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011; 8: 277287.
  • 19
    National Study of HIV in Pregnancy and Childhood. National surveillance data. Available at http://www.nshpc.ucl.ac.uk (accessed April 2012).
  • 20
    Tariq S, Townsend CL, Cortina-Borja M et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. J Acquir Immune Defic Syndr 2011; 57: 326333.
  • 21
    Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011. Wilmington, NC, Registry Coordinating Center, 2011. Available at http://www.APRegistry.com (accessed April 2012).
  • 22
    Ekouevi DK, Coffie PA, Ouattara E et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d′Ivoire. J Acquir Immune Defic Syndr 2011; 56: 183187.
  • 23
    Ford N, Mofenson L, Kranzer K et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24: 14611470.
  • 24
    Ford N, Calmy A, Mofensen L. Safety of efavirenz in first-trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25: 23012304.
  • 25
    Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS 2009; 23: 519524.
  • 26
    Hsu H, Rydzak C, Cotich K et al. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med 2011; 12: 97108.
  • 27
    Currier J, Averitt Bridge D, Hagins D et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153: 349357.